Pieris Pharmaceuticals In... (PIRS)
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 9:00 PM
Pieris Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 42.81M | 25.9M | 31.42M | 29.32M | 46.28M | 29.1M | 25.27M | 5.83M | 2.93M | 5.37M | 9.88M | 11.38M |
| Cost of Revenue | 41.8M | 2.78M | 2.37M | 46.53M | 55M | n/a | n/a | n/a | n/a | n/a | -2.55M | n/a |
| Gross Profit | 1.01M | 23.12M | 29.05M | -17.21M | -8.72M | 29.1M | 25.27M | 5.83M | 2.93M | 5.37M | 12.43M | 11.38M |
| Operating Income | -29.76M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M | -13.68M | -7.2M | 553.83K | -2.18M |
| Interest Income | 1.85M | 721K | 4K | 511K | 1.71M | 1.96M | 152K | 2.32K | n/a | n/a | n/a | 177.13K |
| Pretax Income | -24.54M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M | -13.85M | -9.85M | 66.2K | -2.32M |
| Net Income | -24.54M | -31.25M | -43.37M | -37.23M | -23.75M | -26.75M | -17.65M | -22.8M | -14.06M | -9.85M | 66.2K | -2.32M |
| Selling & General & Admin | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.99M |
| Research & Development | 41.8M | 52.98M | 66.66M | 46.53M | 55M | 41.49M | 22.29M | 19.7M | 8.24M | 5.6M | 9.41M | 10.85M |
| Other Expenses | 13.91M | -8.17M | -3.69M | -3.66M | -26K | 1.8M | -2.1M | 119.5K | 10.9K | 3K | 6.31K | n/a |
| Operating Expenses | 72.57M | 61.2M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 1.95M | 2.32K | 184.65K | 2.65M | 493.94K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 280.86K |
| Cost & Expenses | 72.57M | 61.2M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Income Tax | n/a | -2.02M | -2.37M | 164K | -1.71M | -312K | 1.1M | 161.97K | 203.87K | -18 | 487.63K | 22.00 |
| Shares Outstanding (Basic) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| Shares Outstanding (Diluted) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| EPS (Basic) | -21.8 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.7 | -20.62 | 0.45 | -38.68 |
| EPS (Diluted) | -21.8 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.7 | -20.62 | 0.45 | -38.68 |
| EBITDA | -22.76M | -30.5M | -43.37M | -31.61M | -26.12M | -30.26M | -14.22M | -22.4M | -13.37M | -6.83M | 938.5K | -1.8M |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570K | 369K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |